A trial of abiraterone with either dactolisib or buparlisib for prostate cancer that is no longer responding to hormone therapy

This trial looked at abiraterone with either dactolisib or buparlisib for prostate cancer. It was for people whose cancer had continued to grow despite having hormone therapy.

The trial was open for people to join between 2012 and 2014. The team analysed the results in 2016. There are links to more information in the ‘Summary of results’ section below.